...
首页> 外文期刊>Heart >Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient.
【24h】

Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient.

机译:甘油三酯和患dyslipidaemia:扩展超出了他汀类药物治疗高风险心血管病人。

获取原文
获取原文并翻译 | 示例
           

摘要

Although statins significantly decrease the incidence of cardiovascular disease (CVD), residual CVD risk remains high. This may partly be due to uncorrected atherogenic dyslipidaemia. The driving force behind atherogenic dyslipidaemia is hypertriglyceridaemia, which results from hepatic oversecretion and/or hypocatabolism of triglyceride-rich lipoproteins, and is typical of type 2 diabetes and metabolic syndrome. Persistent atherogenic dyslipidaemia in patients treated with a statin according to low-density lipoprotein-cholesterol goals may be corrected with niacin, fibrates or n-3 fatty acids. Clinical trial evidence to inform best practice is limited, but new data support adding fenofibrate to a statin. A consistent feature of fibrate clinical trials is the specific benefit of these agents in dyslipidaemic patients and the improvement in diabetic retinopathy with fenofibrate. Ongoing clinical trials may provide good evidence for adding niacin to a statin. Low-dose n-3 fatty acids could be used routinely after a myocardial infarction, but the value of higher doses of n-3 fatty acids in reducing CVD risk remains to be demonstrated.
机译:虽然他汀类药物明显减少心血管疾病(CVD)的发生率,残余CVD风险仍然很高。是由于未修正的粥样硬化dyslipidaemia。患背后的驱动力dyslipidaemia hypertriglyceridaemia,结果肝oversecretion和/或hypocatabolism triglyceride-rich脂蛋白,是典型的2型糖尿病和代谢并发症状他汀类药物患者根据低密度脂蛋白胆固醇的目标纠正和烟酸,一类或n - 3脂肪酸酸。练习是有限的,但添加新数据支持他汀类药物的非诺贝特。fibrate临床试验是特定的利益dyslipidaemic病人和这些代理改善糖尿病性视网膜病变非诺贝特。他汀类药物添加烟酸的充分证据。低剂量的n - 3脂肪酸可以常规使用心肌梗死后,但的价值高剂量的n - 3脂肪酸减少心血管疾病风险仍有待证明。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号